NEXTCURE, INC Operating Lease Right-of-Use Assets
NEXTCURE, INC (NXTC) had Operating Lease Right-of-Use Assets of $2.40 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-18
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.40M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $2.62M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $2.79M.
- 2025-06-30: Operating Lease, Right-of-Use Asset $2.95M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-03-31 | $2.40M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.62M S-4 · filed 2026-08-18 |
| 2025-09-30 | $2.79M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.95M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.11M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $3.26M S-4 · filed 2026-08-18 |
| 2024-09-30 | $3.42M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $3.56M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $3.63M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $4.40M 10-K · filed 2025-03-06 |
| 2023-09-30 | $4.56M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.71M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.87M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $5.02M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |